Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation.
Andrea D. ThompsoniD, Adam S. HelmsiD, Anamika Kannan, Jaime M. YobiD, Neal K. LakdawalaiD, Samuel G. WittekindiD, Alexandre C. PereiraiD, Daniel Louis JacobyiD, Steven D. ColaniD, Euan Angus AshleyiD, Sara SaberiiD, James S. WareiD, Jodie InglesiD, Christopher SemsarianiD, Michelle MichelsiD, Francesco MazzarottoiD, Iacopo OlivottoiD, Carolyn Yung HoiD, Sharlene M. DayiD, SHaRe investigators
Abstract
PurposeVariants in MYBPC3 causing loss-of-function are the most common cause of HCM. However, a substantial number of patients carry missense variants of uncertain significance (VUS) in MYBPC3. We hypothesize that a structural-based algorithm, STRUM, which estimates the effect of missense variants on protein folding, will improve clinical risk stratification of patients with HCM and a MYBPC3 VUS. MethodsAmong 7,963 patients in the multi-center Sarcomeric Human Cardiomyopathy Registry, 120 unique missense VUSs in MYBPC3 were identified. Variants were evaluated for their effect on subdomain folding and a stratified time-to-event analysis for an overall composite endpoint (first occurrence of ventricular arrhythmia, heart failure, all-cause mortality, atrial fibrillation, and stroke) was performed for patients with HCM and a MYBPC3 missense VUS. ResultsWe demonstrated that patients carrying a MYBPC3 VUS predicted to cause subdomain misfolding (STRUM +, {Delta}{Delta}G [≤]-1.2 kcal/mol) exhibited a higher rate of adverse events compared to those with a STRUM-VUS (Hazard Ratio=2.29, P=0.0282). In silico saturation mutagenesis of MYBPC3 identified 4,943/23,427 (21%) missense variants that were predicted to cause subdomain misfolding. ConclusionsSTRUM enables clinical risk stratification of patients with HCM and a MYBPC3 VUS and has the capacity to improve prognostic predictions and clinical decision making.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 16
- FWCI
- 1.68
- Field percentile
- top 15%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Thermodynamic destabilization informs pathogenicity assessment of a variant of uncertain significance in cardiac myosin binding protein C
María Rosaria Pricolo, Elías Herrero‐Galán, … Giulia Frisso·Journal of Cardiovascular Translational ResearchPeer-reviewed·Feb 7, 2020
- Pathogenic MYBPC3 missense variants alter protein-protein interactions within the sarcomere
Andrea D. Thompson, Chelsea Pankiewicz, … Sharlene M. Day·bioRxiv·Jul 21, 2026
- Scaled multidimensional assays of variant effect identify sequence-function relationships in hypertrophic cardiomyopathy
Yuta Yamamoto, Kaiser Chua, … Victoria Nicole Parikh·CirculationPeer-reviewed·Jul 12, 2026
- MYBPC3 D389V Variant Induces Hypercontractility in Cardiac Organoids
Darshini A. Desai, Taejeong Song, … Sakthivel Sadayappan·CellsPeer-reviewed·Nov 19, 2024
- Comprehensive Genetic Study of Russian Hypertrophic Cardiomyopathy Identifies MYBPC3 c.3697C>T as the Predominant Variant in Pediatric and Adult Cohorts
Leila A. Gandaeva, Чумакова Ольга Сергеевна, … Kirill Victorovich Savostyanov·medRxiv·Nov 5, 2025
- Genotype-Phenotype Correlations Identify Phenotypic Differences in Sarcomere Mutation-Positive Hypertrophic Cardiomyopathy in the NHLBI HCM Registry
Jonathan Chan, Christopher Grace, … Anuj Goel·medRxiv·Jul 30, 2026